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Summary
Relevant secondary mitral regurgitation occurs in 35–
50% of patients with chronic heart failure and is asso-
ciated with increased mortality.
Surgical management of patients with mitral valve re-
gurgitation and heart failure remains controversial. 
There are several questions which are not sufficiently 
clarified because of a lack of prospective randomised 
controlled trials: (1.) The indication for concomitant mi-
tral valve surgery in patients undergoing coronary ar-
tery bypass grafting (CABG) with moderate to severe 
mitral valve regurgitation; (2.) the management of func-
tional mitral valve regurgitation; (3.) the appropriate 
surgical strategy: repair or chordal-sparing replace-
ment.
Key words: mitral valve surgery; heart failure; func-
tional mitral regurgitation; ischaemic mitral regurgita-
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Pathophysiology of functional mitral  
regurgitation in heart failure
Primary organic mitral valve regurgitation and sec-
ondary, functional mitral regurgitation (MR) are two 
different entities. The former is a valvular disease 
whereas the latter is a ventricular disease. Functional 
MR in patients with severe left ventricular dysfunction 
is a consequence of distorted left ventricular geometry 
[4, 5]. Basically, functional MR can be caused by two 
different ventricular pathologies: ischaemic cardiomyo-
pathy and idiopathic dilated cardiomyopathy. In both 
diseases, changes in left ventricular geometry and left 
ventricular dilatation lead to a displacement of one or 
both papillary muscles. This mechanism pulls the leaf-
lets into the left ventricle (tethering), which results in 
tenting of the valve below the plane of the annulus. 
Tethering of the mitral leaflets leads to a reduced area 
of leaflet coaptation (fig. 1). It has been reported that 
functional MR, in addition, results 
in a dilated and deformed mitral 
annulus, although the leaflets are 
usually morphologically normal 
[6]. It has been shown recently that 
the leaflets of the valve may also 
suffer from this pathology and un-
dergo visible histological and anatomical remodelling: 
The chords become stiffer and restrictive, and the leaf-
lets become stiffer, more stretched and thicker [5].
Several authors have demonstrated that MR induces 
further left ventricular dilatation through neurohu-
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Figure 1
Pathophysiology of functional mitral regurgitation. Changes in left ven-
tricular geometry and left ventricular dilatation lead to a displacement 
of one or both papillary muscles. This mechanism pulls the mitral 
leaflets into the left ventricle (tethering). The triangle represents the 
tenting area (area enclosed between the annular plane and the mitral 
leaflets). (AML = anterior mitral leaflet; PML = posterior mitral leaflet;  
a = anterior mitral leaflet angle; b = posterior mitral leaflet angle;  
d = coaptation depth).
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pair, especially restrictive annuloplasty, in functional 
MR has, however, not been clarified because of the lack 
of results of prospective randomised trials. A ran-
domised clinical trial is currently being performed by 
the Cardiothoracic Surgical Trials Network in order to 
answer this question. In this study patients with se-
vere MR secondary to chronic ischaemic cardiomyo- 
pathy are randomised to either mitral valve replace-
ment or mitral valve repair.
Predictors of unsuccessful or not durable mitral valve 
repair after restrictive annuloplasty have been defined 
and are summarised in table 1 [13]. These predictors 
may be helpful for planning surgery, especially with re-
gard to the question of whether to perform a repair or 
a valve replacement in the first instance.
Results of mitral valve surgery in patients with 
functional mitral regurgitation and heart failure
It is hard to draw concrete conclusions from data with 
regard to mitral valve surgery for functional MR in 
heart failure patients since only a few prospective ran-
domised trials exist and most evidence is based upon 
retrospective and observational studies.
Mitral valve surgery for functional MR can be achieved 
with low operative mortality (1.6–5%) and different 
studies have shown that it leads to symptomatic im-
provement and a better quality of life [1, 22–24]. Fur-
thermore, several authors showed that successful sur-
gical treatment of functional MR has the potential to 
lead to reverse remodelling of the diseased left ventri-
cle [24–26]. Despite obvious improvements in symp-
tomatology, the prognostic value of mitral valve sur-
gery in heart failure patients remains unclear. Wu et 
al. retrospectively analysed consecutive patients with 
significant MR and left ventricular systolic dysfunction 
who were treated at the University of Michigan be-
tween 1995 and 2002. A total of 682 patients were iden-
tified and divided into two groups according to their 
therapy, either mitral valve annuloplasty or medical 
therapy. They were able to show that there is no sur-
vival benefit with mitral valve annuloplasty [27].
One difficult aspect of mitral valve repair in patients 
with functional MR is the problem of recurrence rates 
of up to 30% in the initial years after surgery, which 
again negatively affects the course of heart failure and 
survival in these patients [1, 12, 28, 29]. With this in 
mind, the lack of survival benefit with mitral valve an-
nuloplasty for functional MR in heart failure patients 
might be related to the less durable relief of MR with 
mitral valve annuloplasty [1]. Therefore, chordal-spar-
ing mitral valve replacement might show a mortality 
benefit owing to its durable relief of MR, and it should 
certainly not be regarded as surgical failure. This issue 
needs to be investigated in future randomised prospec-
tive trials in order to identify the best surgical treat-
ment for these patients.
moral and cytokine activation [7–9]. Therefore, in pa-
tients with heart failure and significant functional MR 
a vicious cycle evolves, which eventually leads to termi-
nal cardiac failure if the remodelling of the ventricle or 
MR is not reversed [10–12].
Surgical management
The basic principle of the surgical treatment of func-
tional MR is to restore coaptation of the mitral leaflets 
by reshaping the mitral annulus with reduction of the 
septolateral distance, so that the anterior mitral leaflet 
covers the complete orifice of the mitral valve [5]. This 
is achieved by means of a restrictive, undersized annu-
loplasty (fig. 2). An annuloplasty ring is implanted that 
is at least two sizes smaller than the ring that would 
have been chosen on the basis of measuring the inter-
trigonal distance and the surface of the anterior leaflet 
as a reference [13].
With regard to the annuloplasty ring used for the treat-
ment of functional MR, Spoor et al. and Silbermann et 
al. were able to show that complete and rigid annulo-
plasty rings ensure better outcomes than partial and 
flexible rings [14, 15].
Further surgical techniques for repair of functional MR 
include anterior leaflet augmentation with a pericar-
dial patch when the anterior leaflet length is less than 
25 mm, in order to increase the coaptation area [16, 
17], or the addition of the edge-to-edge technique to the 
annuloplasty [18]. In the case of increased tethering of 
second-order chords of the anterior leaflet, mobility of 
the leaflet can be increased by cutting these second- 
order chords [5].
In patients where successful and durable repair is 
questionable or who show no potential for reverse re-
modelling, chordal-sparing mitral valve replacement is 
a good alternative. Several studies showed no long-
term mortality difference in patients with ischaemic 
MR undergoing mitral valve replacement rather than 
mitral valve repair [19–21]. The exact role of mitral 
valve replacement in comparison to mitral valve re-
Figure 2
Schematic illustration of the restrictive annuloplasty technique.
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In contrast Deja et al. reported a benefit with regard to 
early and long-term survival from adding mitral valve 
annuloplasty to CABG surgery, as compared with 
CABG or medical therapy alone. They performed a sur-
vival analysis of 1,212 patients enrolled in the Surgical 
Treatment for Ischaemic Heart Failure (STICH) trial 
to investigate the impact of adding mitral valve repair 
in a subset of patients with moderate to severe chronic 
ischemic MR prospectively randomised, in accordance 
with the study design, to receive CABG or optimised 
medical therapy [33, 34].
Results of surgery for functional mitral regurgi-
tation in patients with dilated cardiomyopathy
With regard to surgical therapy of functional MR in pa-
tients with dilated cardiomyopathy, Acker et al. pub-
lished results from 193 patients prospectively ran-
domised to mitral valve repair alone or mitral repair 
plus implantation of a left ventricular passive restraint 
device (CorCap, Acorn Cardiovascular, USA). They re-
ported a low 30-day mortality of 1.6% and survival rates 
of 86.5% and 85.2%, respectively, at 1 and 2 years after 
surgery. They were able to show significant evidence of 
reverse remodelling and symptomatic benefit after mi-
tral valve repair [35]. DeBonis et al. also proved the 
benefit of mitral valve repair in heart failure patients 
with functional MR and end-stage dilated cardiomyopa-
thy. They were able to show a significant improvement 
in New York Heart Association (NYHA) functional 
class. In patients with a coaptation depth of more than 
10 mm they added the edge-to-edge technique to a re-
strictive annuloplasty and found a lower recurrence 
rate of significant MR than in the patients with restric-
tive annuloplasty alone (3.7% vs 21.7%) [18].
Indications for surgery of functional mitral 
regurgitation (ESC Guidelines)
The therapy of functional MR in heart failure patients 
is addressed in the European Society of Cardiology 
(ESC) guidelines on the management of valvular heart 
disease and the ESC heart failure guidelines, both pub-
lished in 2012.
In patients with severe MR undergoing CABG surgery, 
the addition of mitral repair is a class I indication in 
patients with a left ventricular ejection fraction (LVEF) 
of more than 30% and a class IIa indication in patients 
with a LVEF of less than 30%. In patients with moder-
ate MR for whom CABG surgery is planned, mitral 
valve repair is a class IIa indication. In patients with 
severe MR, a LVEF of more than 30% and no option for 
revascularisation, mitral valve repair represents a 
class IIb indication in the presence of persisting symp-
toms despite optimal medical management (including 
cardiac resynchronisation therapy (CRT) if indicated) 
and low comorbidity.
Best outcomes with regard to reverse ventricular re-
modelling after restrictive annuloplasty were achieved 
in patients with small preoperative left ventricular size 
(left ventricular end-diastolic diameter (LVEDD) less 
than 65 mm) [24, 25]. The potential for reverse remod-
elling is an important aspect to consider when recom-
mending mitral surgery in heart failure patients. Be-
sides the absence of severe ventricular dilatation, there 
are other predictors for favourable reverse remodelling 
including a lower sphericity index and the presence of 
left ventricular contractile reserve [1]. The degree of 
contractile reserve in particular is a predictor of left 
ventricular function after mitral valve repair in heart 
failure patients and should be included in the preoper-
ative assessment [30, 31].
It is important to mention that an individualised ap-
proach to such patients is essential for good outcomes. 
In particular, patients with predictors for less durable 
or unsuccessful mitral valve repair (table 1) should be 
identified and because chordal sparing mitral valve re-
placement might sometimes be the better approach for 
such patients.
Table 1 
Predictors of recurrent mitral regurgitation after restrictive annuloplasty 
in patients with functional mitral regurgitation.
Excessive tethering (coaptation depth >10 mm)
Posterior mitral leaflet angle >45°
Distal anterior mitral leaflet angle >25°
Systolic tenting area >2.5 cm
2
End-systolic interpapillary muscle distance >20 mm
Systolic sphericity index >0.7
Left ventricular end-diastolic diameter >65 mm
Complex multiple regurgitant jets
Mild annular dilatation
Advanced left ventricular remodelling
With regard to the underlying ventricular disease, two 
different groups can be identified: patients with MR 
due to ischaemic or idiopathic dilated cardiomyopathy. 
The treatment of heart failure patients with ischaemic MR 
is especially controversial.
Results of surgery for functional mitral regurgita-
tion in patients with ischaemic cardiomyopathy
In an observational study in patients with moderate to 
severe functional ischemic MR, Mihaljevic et al. exam-
ined the benefit of adding mitral valve annuloplasty 
(MVA) to a coronary artery bypass graft (CABG) proce-
dure, compared with merely performing CABG sur-
gery. Based on their results in 390 patients with a me-
dian follow-up of four years (CABG and MVA) and five 
years (CABG alone), they concluded that the addition 
of mitral valve annuloplasty to CABG surgery did not 
improve long-term functional status or survival com-
pared with CABG alone [32].
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tients, since, in experienced centres, it can be achieved 
with low operative mortality and postoperative symp-
tomatic benefit.
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Figure 3
Decision algorithm for the treatment of functional mitral regurgitation in heart 
failure patients with severely depressed LVEF based on the ESC guidelines.
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